O7125
L-オルニチン L-アスパラギン酸塩
≥98% (TLC)
別名:
(S)-2,5-ジアミノペンタン酸 L-アスパラギン酸塩
ログインで組織・契約価格をご覧ください。
サイズを選択してください
現在、価格および在庫状況を閲覧できません。
この商品について
実験式（ヒル表記法）:
C9H19N3O6
CAS番号:
分子量:
265.26
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:
スキップする
製品名
L-オルニチン L-アスパラギン酸塩, powder
InChI key
IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
InChI
1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
SMILES string
NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O
assay
≥98% (TLC)
form
powder
color
white to off-white
storage temp.
2-8°C
Quality Level
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
1 of 4
当該品目 | O2375 | O4386 | 75490 |
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (TLC) | assay ≥99% | assay ≥99% | assay ≥99.0% (AT) |
| storage temp. 2-8°C | storage temp. - | storage temp. - | storage temp. - |
| color white to off-white | color white | color white | color - |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 100 |
Biochem/physiol Actions
L-オルニチンL-アスパラギン酸は、アルギナーゼによるアルギニン分解の代謝物です。本化合物は筋肉中のアンモニア無毒化を亢進することにより血中アンモニア濃度を低下させ、肝硬変においては肝性脳症の重症度を軽減することが示されています。
Other Notes
アルギナ-ゼによるアルギニンの分解産物です。
保管分類
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Imre Fehérvári et al.
Magyar sebeszet, 65(2), 58-62 (2012-04-20)
About 6500-7000 people/year die in Hungary due to liver cirrhosis which is often complicated with hepatic encephalopathy (HE). While conventional interpretation is that hepatic encephalopathy is a consequence of high blood ammonia level, recent data indicate that the degree of
Shahab Abid et al.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 21(11), 666-671 (2011-11-15)
To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy (HE). Randomized placebo controlled study. The Aga Khan University Hospital, Karachi in the year 2003-2004. Patients with HE were randomized to receive LOLA
José Luis Pérez Hernández et al.
Annals of hepatology, 10 Suppl 2, S66-S69 (2012-01-18)
Introduction. Hepatic encephalopathy (HE) refers to a complex neuropsychiatric syndrome that is progressive but potentially reversible and may have a significant impact on quality of life, as it is characterized by alterations in cognitive function, behavior and personality as well
Takeyori Saheki et al.
Scientific reports, 9(1), 4179-4179 (2019-03-14)
Previous studies using citrin/mitochondrial glycerol-3-phosphate (G3P) dehydrogenase (mGPD) double-knockout mice have demonstrated that increased dietary protein reduces the extent of carbohydrate-induced hyperammonemia observed in these mice. This study aimed to further elucidate the mechanisms of this effect. Specific amino acids
Mark J W McPhail et al.
Neurology, 80(11), 1041-1047 (2013-02-22)
To measure changes in psychometric state, neural activation, brain volume (BV), and cerebral metabolite concentrations during treatment of minimal hepatic encephalopathy. As proof of principle, 22 patients with well-compensated, biopsy-proven cirrhosis of differing etiology and previous minimal hepatic encephalopathy were
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）